Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological…

Read MoreMerck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals. If approved,…

Read MoreMerck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

 Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology. Effective today, Chris Boshoff, M.D., PhD, will join Pfizer’s Executive Leadership…

Read MorePfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

Fisher & Paykel Healthcare Director Donal O’Dwyer to retire, Graham McLean to join the Board as non-executive director

Fisher & Paykel Healthcare Director Donal O’Dwyer has announced his intention to retire as a director of the company with effect from 31 December 2023. The company also announced it has appointed Graham McLean to the Board as a non-executive director…

Read MoreFisher & Paykel Healthcare Director Donal O’Dwyer to retire, Graham McLean to join the Board as non-executive director

Centene’s Texas Subsidiary Announces Successful Reprocurement of STAR+PLUS Contract

Centene Corporation (NYSE: CNC) announced today that its Texas subsidiary, Superior HealthPlan (Superior), will continue to provide the aged, blind and disabled (ABD) population with healthcare coverage through the STAR+PLUS program. A new six-year contract, with a maximum of three additional two-year extensions,…

Read MoreCentene’s Texas Subsidiary Announces Successful Reprocurement of STAR+PLUS Contract